Page last updated: 2024-08-18

quinuclidines and Cancer of Skin

quinuclidines has been researched along with Cancer of Skin in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Awada, A; Ghanem, G; Journe, F; Krayem, M; Marine, JC; Morandini, R; Najem, A; Salès, F; Sibille, C; van Kempen, LC; Wiedig, M	1
Madar, S; Rotter, V; Stambolsky, P	1

Other Studies

2 other study(ies) available for quinuclidines and Cancer of Skin

Article	Year
p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. European journal of cancer (Oxford, England : 1990), 2016, Volume: 55 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Genetic Predisposition to Disease; Humans; Indoles; Male; Melanoma; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinuclidines; Signal Transduction; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Suppressor Protein p53; Vemurafenib; Xenograft Model Antitumor Assays	2016
Unleash the wild type: restoration of p53 suppressive activity in skin cancer. Cell cycle (Georgetown, Tex.), 2011, Mar-01, Volume: 10, Issue:5 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Quinuclidines; RNA Interference; RNA, Small Interfering; Skin Neoplasms; Tumor Suppressor Protein p53	2011

Article

Year

p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.

European journal of cancer (Oxford, England : 1990), 2016, Volume: 55

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Genetic Predisposition to Disease; Humans; Indoles; Male; Melanoma; Mice, Nude; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinuclidines; Signal Transduction; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Suppressor Protein p53; Vemurafenib; Xenograft Model Antitumor Assays

2016

Unleash the wild type: restoration of p53 suppressive activity in skin cancer.

Cell cycle (Georgetown, Tex.), 2011, Mar-01, Volume: 10, Issue:5

Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Quinuclidines; RNA Interference; RNA, Small Interfering; Skin Neoplasms; Tumor Suppressor Protein p53

2011